Board of Directors
Nitec Pharma AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines and effective treatment solutions for chronic inflammation and pain-related diseases. The Company seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets.
Nitec’s most advanced product candidate is Lodotra™, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. A dossier was submitted in 2006 in order to obtain marketing authorization in 15 European countries using the decentralized procedure, and after successful completion of this decentralized procedure, the marketing authorization in these countries is expected in the second half of 2008. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotra™ for the treatment of the signs and symptoms of RA including morning stiffness. Lodotra™ is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR).
Nitec’s second product candidate is TruNoc (tarenflurbil), which is being developed as a treatment of neuropathic pain, osteoarthritis and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain and osteoarthritis.
Nitec is a spin-out of Merck KGaA and is headquartered in the Basel region of Switzerland.
Meet Nitec Pharma at the following conferences:
Sachs Associates 8th Annual Biotech in Europe Investor Forum, 23-24 September 2008 in Zürich Rodman & Renshaw 10th Annual Healthcare Conference, November 10-12, 2008 in New York BIO-Europe 2008 14th Annual International Partnering Conference, November 17-19 in Mannheim/Heidelberg Germany
